Monoclonal Antibodies Elimination in Breast Cancer Patient

Inclusion Criteria

• •A diagnosed cancer
• •patient treated by bevacizumab or trastuzumab
• •Life expectancy of at least 3 months
• •For the women: menopausal women for at least 24 months, sterilized surgically, or, for the women old enough to procreate, use a method of effective contraception (oral contraceptives, contraceptive injections, intra-uterine devices, method of the double barrier, the contraceptive patches). This contraception will have to be pursued during 6 months after the end of the treatment by bevacizumab or by trastuzumab.